BriaCell Announces Private Placement of up to $600,000
20 September 2019 - 5:03PM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage
biotechnology company specializing in targeted immunotherapy for
advanced breast cancer, is pleased to announce a non-brokered
private placement (the “Private Placement”) of up to approximately
8,571,428 common shares in the capital of the Company for gross
proceeds of up to approximately C$600,000 at a price per common
share of C$0.07.
The Company intends to use the proceeds from the
Private Placement to fund research and development, and for general
working capital and general corporate purposes.
The closing of the Offering is scheduled to
occur on or about September 26, 2019. All securities issued
under the Private Placement will be subject to a hold period
expiring 4 months plus 1 day following the closing date of the
Private Placement. The Private Placement remains subject to final
approval from the TSX Venture Exchange.
The securities have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the
“U.S. Securities Act”), or any U.S. state securities laws, and may
not be offered or sold in the United States or to, or for the
account or benefit of, United States persons absent registration or
an applicable exemption from the registration requirements of the
U.S. Securities Act and applicable U.S. state securities laws. This
press release shall not constitute an offer to sell or the
solicitation of an offer to buy securities in the United States,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is currently conducting a Phase I/IIa
clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a
Combination Study with immune checkpoint inhibitors such as
pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.
(NYSE: MRK)]. The Combination Study is listed in ClinicalTrials.gov
as NCT03328026.
BriaCell also has a non-exclusive clinical trial
collaboration with Incyte Corporation to evaluate the effects of
combinations of novel clinical candidates. Under the agreement,
Incyte and BriaCell will be evaluating novel combinations of
compounds from Incyte’s development portfolio with Bria-IMT™ in
advanced breast cancer patients.
BriaCell is developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:BriaCell
Therapeutics Corp.:Farrah DeanManager, Corporate
DevelopmentEmail: farrah@BriaCell.comPhone: 1-888-485-6340
Jamieson BondarenkoDirector and Chairman of the
Boardjbondarenko@briacell.com
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024